Home / Categories / By country / Europe / UK / HCP - UK
Click to view full size image
Click here for details on how to download this file to your desktop.


(fluticasone furoate and vilanterol inhalation powder)

24 hrs

The only once-daily ICS/LABA that provides 24-hour continuous efficacy for your patients with asthma

Now that worth putting up in lights...

RELVAR ellipta
(fluticasone furoate and vilanterol inhalation powder)

Relvar is generally well tolerated in asthma

Indications: Asthma: Regular treatment of asthma in patients >12 years and older not adequately controlled on inhaled corticosteroids and “as needed” short-acting inhaled B2-agonists, where a long-acting (B2-agonist and inhaled corticosteroid combination is appropriate. COPD: Symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

Other ads from this campaign
Ads with similar themes

Brand: Relvar Ellipta
Generic name/category: Fluticasone Fuorate and Vilanterol inhalation
Company: Theravance and GSK
Country/Market: UK, Europe
Indication(s)/Disease: Asthma and COPD
Target: Healthcare Professional (HCP)
Tagline: Now that worth putting up in lights...
Size/duration: Single-page
Publication/Aired: BMJ General Practice - The BMJ - October 10, 2015

See more Relvar Ellipta ads here
Rate this file (No vote yet)
About Subscriptions Contact us Twitter LinkedIn